Navigation Links
New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
Date:5/5/2008

- Studies Evaluated Improvement in Symptoms Both in the Short and Long Term

-

WILMINGTON, Del., May 5 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced new study data on SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients. The results from the studies were presented today at the 161st Annual Meeting of the American Psychiatric Association (APA) in Washington, DC. In February 2008, the company submitted a supplemental new drug application (sNDA) for SEROQUEL XR for the treatment of MDD as monotherapy, adjunct therapy, and maintenance therapy. AstraZeneca plans to submit a sNDA for SEROQUEL XR for the treatment of GAD, including maintenance of antianxiety effect, during the second quarter of 2008.

The SEROQUEL XR clinical development programs for MDD and GAD included seven Phase III, placebo-controlled studies in MDD as well as four Phase III, placebo-controlled studies in GAD. The three MDD studies presented today investigated SEROQUEL XR in the treatment of adult patients diagnosed with MDD-as monotherapy in both short-term and maintenance treatment and as short- term adjunct treatment versus placebo.(1-3) The two GAD studies presented today investigated treatment with SEROQUEL XR in adult patients diagnosed with GAD-as monotherapy in both short-term and maintenance treatment versus placebo.(4,5) Across all MDD and GAD studies presented today, efficacy with SEROQUEL XR was superior to placebo, as assessed by the primary endpoints. In addition, adverse events reported for SEROQUEL XR in these studies were generally similar to those reported in previous clinical trials with quetiapine (See detailed study data below).(1-5)

MDD affects approximately 15 million American adults and studies have shown that at least one-third of patients with MDD treated with antidepressants fa
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
2. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
3. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
4. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
5. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
6. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
7. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
8. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
11. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
(Date:10/30/2014)... , Oct. 29, 2014   ViaDerma, ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual ... mass transfer of pharmaceutical active ingredients to penetrate ... immediate localized therapy. The transdermal delivery method also ...
(Date:10/30/2014)... Realty Trust, Inc. (NYSE: BMR ), ... sciences, today announced financial results for the third ... Quarter 2014 Highlights Financial and Operating Performance ... quarter representing approximately 657,700 square feet,  contributing to: ... of approximately 219,700 square feet; and , ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 2BioMed Realty Trust Reports Third Quarter 2014 Financial Results 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 4BioMed Realty Trust Reports Third Quarter 2014 Financial Results 5BioMed Realty Trust Reports Third Quarter 2014 Financial Results 6BioMed Realty Trust Reports Third Quarter 2014 Financial Results 7BioMed Realty Trust Reports Third Quarter 2014 Financial Results 8BioMed Realty Trust Reports Third Quarter 2014 Financial Results 9BioMed Realty Trust Reports Third Quarter 2014 Financial Results 10BioMed Realty Trust Reports Third Quarter 2014 Financial Results 11BioMed Realty Trust Reports Third Quarter 2014 Financial Results 12BioMed Realty Trust Reports Third Quarter 2014 Financial Results 13BioMed Realty Trust Reports Third Quarter 2014 Financial Results 14BioMed Realty Trust Reports Third Quarter 2014 Financial Results 15BioMed Realty Trust Reports Third Quarter 2014 Financial Results 16BioMed Realty Trust Reports Third Quarter 2014 Financial Results 17BioMed Realty Trust Reports Third Quarter 2014 Financial Results 18BioMed Realty Trust Reports Third Quarter 2014 Financial Results 19BioMed Realty Trust Reports Third Quarter 2014 Financial Results 20BioMed Realty Trust Reports Third Quarter 2014 Financial Results 21
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager ... help people save money through its innovative discount card ... drugs in the new health care system, the Paramount ... the relationship between consumers, businesses and the pharmacy industry. ... face today with medical costs is the rising price ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Advisors Transitioning to Independence, SAN FRANCISCO, ... new relationship with national human resources,outsourcing company ... for,independent investment advisors and their employees. As ... advisors who custody,assets with Schwab will now ...
... 15 Dong-A PharmTech Co. Ltd,announced today the signing ... to market in Russia Dong-A,s erectile,dysfunction drug which is ... Under the terms of the agreement, Otechestvennye Lekarstva ... both upfront fees and,running royalty on sales for the ...
... as well, 266,604 fewer patients would die annually, survey ... in the top-ranked hospitals in the United States are ... the lowest-rated hospitals, according to a new study from ... HealthGrades Hospital Quality in America Study looked at 41 ...
... scientists this month joined Biomoda, Inc. (OTC Bulletin ... assist with,commercialization efforts of the company,s early lung ... "Constance Dorian brings strong analytical skills and significant,understanding ... She will be an important asset in all ...
... Researchers and Health Professionals Gather at Mental ... November 2nd, NEW YORK, Oct. 15 In ... Long Island Mental Illness,Awareness Day presented by Clubhouse of ... at the Huntington Hilton in Melville, NY from 8:00,AM ...
... fifth of patients need to work through mental problems ... -- About one in every five people who were ... recommended psychiatric clearance for the procedure, a U.S. study ... screening process in most bariatric surgery programs, notes a ...
Cached Medicine News:Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 3Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 4Health News:Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia 2Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 2Health News:Psychiatric Woes Can Postpone Weight-Loss Surgery 2
... The dual lumen petite ... 1.0 mm catheter (each lumen) ... Dual oval lumen catheters offer ... maximum catheter strength. Dual lumen ...
Our smallest port is available with either a COOK Peel-Away or COOK Micropuncture Introducer Set....
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe...
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
Medicine Products: